[Effect of human bone morphogenetic protein 2, 3, 6, and 12 on osteosarcoma cell line UMR106].
OBJECTIVE
To investigate the effect of human bone morphogenetic protein (hBMPs) 2/3/6 and 12 on osteosarcoma cell UMR106.


METHODS
Adenovirus-BMP2/3/6 and 12 (AdBMP2/3/6 and12) were used to treat the cell line. Their proliferation, apoptosis, and transmigration were detected by Trypan blue exclusion test, TdT-mediated biotinylated-dUTP nick end labeling (TUNEL), acridine orange-ethidium bromide (AO/EB) double fluorescent dye staining, and transwell-room test, respectively. The alkaline phosphatase (ALP) activity was detected to reflect the differentiation of tumors.


RESULTS
Compared with the control groups, the cell survival rate of the experimental groups treated with AdBMP2/3/6 and 12 showed a significant time-dependent decrease (P<0.01). The apoptosis indexes were increased significantly (P<0.01) and the results from TUNEL and AO/EB method were consistent. The cell numbers of transmembrane significantly decreased at 24,48, and 72 h (P<0.01). AdBMP2/3/6 and 12 treatment enhanced the activity of ALP activity from day 3 and this effect might still be observed up to day 9 of the treatment (P<0.01).


CONCLUSIONS
hBMPs2/3/6 and 12 can inhibit the proliferation and transmigration, and induce their apoptosis and differentiation in osteosarcoma cell line UMR106.
Li
Xingxing
X
Department of Biomedical Engineering, Chongqing Medical University, Key Laboratory of Biomedical Engineering of Chongqing, Chongqing 400016, China.
He
Huanling
H
Wu
Limei
L
Ma
Wen
W
Chen
Yinghua
Y
Wei
Jia
J
Miao
Jingkun
J
Zhou
Lan
L
D000256:Adenoviridae / Q000235:genetics / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects*; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology*; D055398:Bone Morphogenetic Protein 3 / Q000494:pharmacology*; D055418:Bone Morphogenetic Protein 6 / Q000494:pharmacology*; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000473:pathology; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D055412:Growth Differentiation Factors / Q000494:pharmacology*; D006801:Humans; D012516:Osteosarcoma / Q000473:pathology*; D011994:Recombinant Proteins / Q000494:pharmacology
C525718:BMP2 protein, human; C525757:BMP3 protein, human; C525816:BMP6 protein, human; D055396:Bone Morphogenetic Protein 2; D055398:Bone Morphogenetic Protein 3; D055418:Bone Morphogenetic Protein 6; D019485:Bone Morphogenetic Proteins; C499470:GDF7 protein, human; D055412:Growth Differentiation Factors; D011994:Recombinant Proteins